Table 2.
Clinicopathological features and treatment patterns of SMARCA4-deficient versus SMARCB1-deficient SNCs.
| Parameters | SMARCA4-def | SMARCB1-def | p-value |
|---|---|---|---|
| (N=45) | (N=139) | ||
| Age | 0.001 | ||
| Mean (SD) | 43.1 (14.8) | 53.2 (17.7) | |
| Median [Min, Max] | 42.0 [18.0, 70.0] | 53.0 [11.0, 95.0] | |
| Gender | 0.901 | ||
| Female | 14 (32.6%) | 45 (33.6%) | |
| Male | 29 (67.4%) | 89 (66.4%) | |
| Nodal metastasis | 1 (5.0%) | 19 (18.6%) | 0.191 |
| Distant metastasis | 7 (35.0%) | 38 (36.9%) | 0.872 |
| Original diagnoses | < 0.001 | ||
| Adenocarcinoma | 0 (0%) | 7 (5.8%) | |
| NEC | 12 (29.3%) | 1 (0.9%) | |
| PDCA | 2 (4.9%) | 10 (8.3%) | |
| SCC | 1 (2.4%) | 29 (24.2%) | |
| SNUC | 3 (7.3%) | 40 (33.3%) | |
| Teratocarcinosarcoma | 23 (56.1%) | 0 (0%) | |
| SMARCB1-deficient | 0 (0%) | 26 (21.7%) | |
| Other | 0 (0%) | 7 (5.8%) | |
| Resection | 0.411 | ||
| Biopsy | 10 (28.6%) | 24 (21.8%) | |
| Resection | 25 (71.4%) | 86 (78.2%) | |
| Radiotherapy | 14 (43.8%) | 85 (78.0%) | < 0.001 |
| Chemotherapy | 18 (56.3%) | 73 (67.0%) | 0.265 |
NEC, neuroendocrine carcinoma; PDCA, poorly differentiated carcinoma; SCC, squamous cell carcinoma; SNUC, sinonasal undifferentiated carcinoma.